Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Novartis 1Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Novartis 1Q

Pharma sales down 9% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Novartis

1Q Revenues: $11.9 billion (-7%)

1Q Earnings: $2.3 billion (-6%)

Comments: Pharmaceutical sales were $7.1 billion in the quarter, down 9%, and included the new oncology assets acquired from GSK (sales of $0.2 billion in March), offset by the negative impact of generic competition, largely for Diovan, Exforge and Vivelle-Dot in the U.S. Growth Products, which include Gilenya, Afinitor, Tasigna, Galvus, Lucentis, Xolair, the COPD portfolio, and Jakavi – generated $2.9 billion, up 25%. Alcon sales were $2.6 billion, down 3% in the quarter. Sandoz sales were $2.2 billion, down 3%. U.S. sales of generics and biosimilars were up 13% (cc), driven by continuing strong performance from recent launches and Fougera sales. The company gained three approvals in oncology in the quarter: Jakavi in polycythemia vera (EU), Farydak in multiple myeloma (U.S.) and Jadenu for chronic iron overload (U.S.).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics